FASN can be used as a biomarker since it is enriched in extracellular vesicles derived from GBM cell lines and human plasma, suggesting that plasma extracellular vesicle levels could be used as a noninvasive biomarker for GBM [27]. The gene discussed is FASN; the disease is glioblastoma.